Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

MELBOURNE, Australia and SAN FRANCISCO: - Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to...

Click to view original post